Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Rupali R. Bhave"'
Autor:
Rebecca Anderson, Lance D. Miller, Scott Isom, Jeff W. Chou, Kristin M. Pladna, Nathaniel J. Schramm, Leslie R. Ellis, Dianna S. Howard, Rupali R. Bhave, Megan Manuel, Sarah Dralle, Susan Lyerly, Bayard L. Powell, Timothy S. Pardee
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-13 (2022)
Combining cytarabine and mitoxantrone with the tricarboxylic acid cycle inhibitor devimistat has been reported in a phase I clinical trial with relapsed or refractory acute myeloid leukaemia (AML). Here, the authors report the outcomes of a phase II
Externí odkaz:
https://doaj.org/article/af7e039587ff405b8de70ccdba887ce2
Autor:
Anjali S. Advani, Anna Moseley, Kristen M. O'Dwyer, Brent L. Wood, Min Fang, Matthew J. Wieduwilt, Ibrahim Aldoss, Jae H. Park, Rebecca B. Klisovic, Maria R. Baer, Wendy Stock, Rupali R. Bhave, Megan Othus, Richard C. Harvey, Cheryl L. Willman, Mark R. Litzow, Richard M. Stone, Elad Sharon, Harry P. Erba
Publikováno v:
J Clin Oncol
PURPOSE Chemotherapy outcomes in older patients with Philadelphia (Ph) chromosome–negative B-acute lymphoblastic leukemia (ALL) are very poor. Here, we evaluated blinatumomab as induction and consolidation therapy followed by prednisone, vincristin
Autor:
Rebecca, Anderson, Lance D, Miller, Scott, Isom, Jeff W, Chou, Kristin M, Pladna, Nathaniel J, Schramm, Leslie R, Ellis, Dianna S, Howard, Rupali R, Bhave, Megan, Manuel, Sarah, Dralle, Susan, Lyerly, Bayard L, Powell, Timothy S, Pardee
Publikováno v:
Nature communications. 13(1)
Devimistat is a TCA cycle inhibitor. A previously completed phase I study of devimistat in combination with cytarabine and mitoxantrone in patients with relapsed or refractory AML showed promising response rates. Here we report the results of a singl
Autor:
Bing He, Chen Zhao, Fengyin Li, Monica L. Guzman, Rupali R. Bhave, Xiaoke Ma, Steven R. Lentz, Hai-Hui Xue, Shuyang Yu, Kai Tan
Publikováno v:
Cell Stem Cell. 21:359-373.e5
Summary Effective treatment of chronic myelogenous leukemia (CML) largely depends on the eradication of CML leukemic stem cells (LSCs). We recently showed that CML LSCs depend on Tcf1 and Lef1 factors for self-renewal. Using a connectivity map, we id
Autor:
Mascarenhas J; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York., Migliaccio AR; Altius Institute for Biomedical Sciences, Seattle, Washington., Kosiorek H; Department of Quantitative Health Sciences, Mayo Clinic, Scottsdale, Arizona., Bhave R; Comprehensive Cancer Center of Atrium Health Wake Forest Baptist, Winston-Salem, North Carolina., Palmer J; Mayo Clinic Scottsdale, Arizona., Kuykendall A; Department of Hematologic Malignancy, Moffitt Cancer Center, Tampa, Florida., Mesa R; Comprehensive Cancer Center of Atrium Health Wake Forest Baptist, Winston-Salem, North Carolina., Rampal RK; Leukemia Service, Department of Medicine, Center for Hematologic Malignancies, Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, New York., Gerds AT; Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio., Yacoub A; The University of Kansas Cancer Center, Westwood, Kansas., Pettit K; University of Michigan, Comprehensive Cancer Center, Ann Arbor, Michigan., Talpaz M; University of Michigan, Comprehensive Cancer Center, Ann Arbor, Michigan., Komrokji R; Department of Hematologic Malignancy, Moffitt Cancer Center, Tampa, Florida., Kremyanskaya M; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York., Gonzalez A; The University of Texas Health Science Center at San Antonio, San Antonio, Texas., Fabris F; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York., Johnson K; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York., Dougherty M; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York., McGovern E; Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, New York., Arango Ossa J; Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, New York., Domenico D; Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, New York., Farnoud N; Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, New York., Weinberg RS; New York Blood Center, New York, New York., Kong A; Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, New York., Najfeld V; Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, New York., Vannucchi AM; University of Florence, Azienda Ospedaliero Universitaria Careggi, Florence, Italy., Arciprete F; Unit of Microscopic and Ultrastructural Anatomy, University Campus Bio-Medico, Rome, Italy., Zingariello M; Unit of Microscopic and Ultrastructural Anatomy, University Campus Bio-Medico, Rome, Italy., Falchi M; National HIV/AIDS Research Center, Istituto Superiore di Sanità, Viale Regina Elena Rome Italy., Salama ME; Sonic Healthcare, Austin, Texas., Mead-Harvey C; Department of Quantitative Health Sciences, Mayo Clinic, Scottsdale, Arizona., Dueck A; Department of Quantitative Health Sciences, Mayo Clinic, Scottsdale, Arizona., Varricchio L; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York., Hoffman R; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2023 Sep 15; Vol. 29 (18), pp. 3622-3632.
Autor:
Reed DR; Section On Hematology and Medical Oncology, Wake Forest University School of Medicine, Wake Forest Baptist Health Comprehensive Cancer Center, Medical Center Boulevard, Winston-Salem, NC, 27012, USA. drreed@wakehealth.edu., Wooster M; Section On Hematology and Medical Oncology, Wake Forest University School of Medicine, Wake Forest Baptist Health Comprehensive Cancer Center, Medical Center Boulevard, Winston-Salem, NC, 27012, USA., Isom S; Section On Hematology and Medical Oncology, Wake Forest University School of Medicine, Wake Forest Baptist Health Comprehensive Cancer Center, Medical Center Boulevard, Winston-Salem, NC, 27012, USA., Ellis LR; Section On Hematology and Medical Oncology, Wake Forest University School of Medicine, Wake Forest Baptist Health Comprehensive Cancer Center, Medical Center Boulevard, Winston-Salem, NC, 27012, USA., Howard DS; Section On Hematology and Medical Oncology, Wake Forest University School of Medicine, Wake Forest Baptist Health Comprehensive Cancer Center, Medical Center Boulevard, Winston-Salem, NC, 27012, USA., Manuel M; Section On Hematology and Medical Oncology, Wake Forest University School of Medicine, Wake Forest Baptist Health Comprehensive Cancer Center, Medical Center Boulevard, Winston-Salem, NC, 27012, USA., Dralle S; Section On Hematology and Medical Oncology, Wake Forest University School of Medicine, Wake Forest Baptist Health Comprehensive Cancer Center, Medical Center Boulevard, Winston-Salem, NC, 27012, USA., Lyerly S; Section On Hematology and Medical Oncology, Wake Forest University School of Medicine, Wake Forest Baptist Health Comprehensive Cancer Center, Medical Center Boulevard, Winston-Salem, NC, 27012, USA., Bhave R; Section On Hematology and Medical Oncology, Wake Forest University School of Medicine, Wake Forest Baptist Health Comprehensive Cancer Center, Medical Center Boulevard, Winston-Salem, NC, 27012, USA., Powell BL; Section On Hematology and Medical Oncology, Wake Forest University School of Medicine, Wake Forest Baptist Health Comprehensive Cancer Center, Medical Center Boulevard, Winston-Salem, NC, 27012, USA., Pardee TS; Section On Hematology and Medical Oncology, Wake Forest University School of Medicine, Wake Forest Baptist Health Comprehensive Cancer Center, Medical Center Boulevard, Winston-Salem, NC, 27012, USA.
Publikováno v:
Annals of hematology [Ann Hematol] 2023 Apr; Vol. 102 (4), pp. 897-906. Date of Electronic Publication: 2023 Mar 01.
Autor:
Mascarenhas JO; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY., Rampal RK; Leukemia Service, Department of Medicine.; Center for Hematologic Malignancies, and.; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY., Kosiorek HE; Department of Health Sciences Research, Mayo Clinic, Scottsdale, AZ., Bhave R; Wake Forest Baptist Health, Winston-Salem, NC., Hexner E; University of Pennsylvania, Philadelphia, PA., Wang ES; Roswell Park Comprehensive Cancer Center, Buffalo, NY., Gerds A; Leukemia and Myeloid Disorders Program, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH., Abboud CN; Washington University in St. Louis School of Medicine, St. Louis, MO., Kremyanskaya M; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY., Berenzon D; Wake Forest Baptist Health, Winston-Salem, NC., Odenike O; The University of Chicago Medicine and Comprehensive Cancer Center, Chicago, IL., Farnoud N; Center for Hematologic Malignancies, and.; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY., Krishnan A; Center for Hematologic Malignancies, and.; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY., Weinberg RS; New York Blood Center, New York, NY., McGovern E; Center for Hematologic Malignancies, and.; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY., Salama ME; Department of Pathology, Mayo Clinic, Rochester, MN., Najfeld V; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY., Medina-Martinez JS; Department of Computational Oncology, Memorial Sloan Kettering Cancer Center, New York, NY., Arango Ossa JE; Department of Computational Oncology, Memorial Sloan Kettering Cancer Center, New York, NY., Levine MF; Department of Computational Oncology, Memorial Sloan Kettering Cancer Center, New York, NY., Zhou Y; Department of Computational Oncology, Memorial Sloan Kettering Cancer Center, New York, NY., Sandy L; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY., Heaney ML; Department of Medicine, Columbia University Medical Center, New York, NY., Levine RL; Leukemia Service, Department of Medicine.; Center for Hematologic Malignancies, and.; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY.; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY; and., Mesa RA; Mays Cancer Center at UT Health San Antonio, San Antonio, TX., Dueck AC; Department of Health Sciences Research, Mayo Clinic, Scottsdale, AZ., Hoffman R; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY.
Publikováno v:
Blood advances [Blood Adv] 2020 Oct 27; Vol. 4 (20), pp. 5246-5256.